Valneva (NASDAQ:VALN) Trading Up 7.1% - Time to Buy?

Key Points

• Valneva shares rose 7.1% to about $7.03 in mid-day trading, though trading volume was roughly 51% below the average session level.
• Analyst sentiment remains mixed: TD Cowen initiated coverage with a Buy rating and a $12 price target, while other analysts maintained Sell ratings. The overall consensus is Hold, with an average target of $9.30.
• The company reported a quarterly loss of $0.40 per share, missing the $0.19 loss estimate, while revenue of $39.37 million also fell short of expectations. Valneva posted negative net margin and return on equity, and analysts expect a full-year loss.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s share price was up 7.1% during mid-day trading on Wednesday . The company traded as high as $6.98 and last traded at $7.0340. Approximately 32,776 shares traded hands during trading, a decline of 51% from the average session volume of 67,036 shares. The stock had previously closed at $6.57.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Valneva in a research note on Tuesday, August 11th. They issued a "buy" rating and a $12.00 price target on the stock. Wall Street Zen upgraded shares of Valneva from a "strong sell" rating to a "sell" rating in a report on Monday, June 1st. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Valneva in a research note on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $9.30.

Valneva Stock Up 6.2%

The stock has a market capitalization of $662.33 million, a price-to-earnings ratio of -3.30 and a beta of 1.67. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The business has a fifty day moving average of $5.57 and a 200 day moving average of $6.67.

Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The business had revenue of $39.37 million during the quarter, compared to analysts' expectations of $44.17 million. As a group, equities analysts predict that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Marex Group plc purchased a new stake in shares of Valneva in the 2nd quarter valued at approximately $64,000. XTX Topco Ltd acquired a new stake in shares of Valneva in the fourth quarter valued at $94,000. Finally, JPMorgan Chase & Co. acquired a new position in Valneva in the 3rd quarter valued at about $124,000. Institutional investors and hedge funds own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva's research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source